Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3)

Qi Zhang; Bridget Riley-Gillis; Lina Han; Yannan Jia; Alessia Lodi; Haijiao Zhang; Saravanan Ganesan; Rongqing Pan; Sergej N. Konoplev; Shannon R. Sweeney; Jeremy A. Ryan; Yulia Jitkova; Kenneth Dunner; Shaun E. Grosskurth; Priyanka Vijay; Sujana Ghosh; Charles Lu; Wencai Ma; Stephen Kurtz; Vivian R. Ruvolo; Helen Ma; Connie C. Weng; Cassandra L. Ramage; Natalia Baran; Ce Shi; Tianyu Cai; Richard Eric Davis; Venkata L. Battula; Yingchang Mi; Jing Wang; Courtney D. DiNardo; Michael Andreeff; Jeffery W. Tyner; Aaron Schimmer; Anthony Letai; Rose Ann Padua; Carlos E. Bueso-Ramos; Stefano Tiziani; Joel Leverson; Relja Popovic; Marina Konopleva

doi:10.1038/s41392-022-00958-4

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3)

Qi Zhang, Bridget Riley-Gillis, Lina Han, Yannan Jia, Alessia Lodi, Haijiao Zhang, Saravanan Ganesan, Rongqing Pan, Sergej N. Konoplev, Shannon R. Sweeney, Jeremy A. Ryan, Yulia Jitkova, Kenneth Dunner, Shaun E. Grosskurth, Priyanka Vijay, Sujana Ghosh, Charles Lu, Wencai Ma, Stephen Kurtz, Vivian R. RuvoloHelen Ma, Connie C. Weng, Cassandra L. Ramage, Natalia Baran, Ce Shi, Tianyu Cai, Richard Eric Davis, Venkata L. Battula, Yingchang Mi, Jing Wang, Courtney D. DiNardo, Michael Andreeff, Jeffery W. Tyner, Aaron Schimmer, Anthony Letai, Rose Ann Padua, Carlos E. Bueso-Ramos, Stefano Tiziani, Joel Leverson, Relja Popovic, Marina Konopleva

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

In the original version of this article, given name of 4th author Yannan Jia was incorrectly published as Yanan Jia. The original article has been corrected.

Original language	English (US)
Article number	110
Journal	Signal Transduction and Targeted Therapy
Volume	7
Issue number	1
DOIs	https://doi.org/10.1038/s41392-022-00958-4
State	Published - Dec 2022

ASJC Scopus subject areas

Genetics
Cancer Research

Access to Document

10.1038/s41392-022-00958-4

Fingerprint

Dive into the research topics of 'Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3)'. Together they form a unique fingerprint.

Cite this

Zhang, Q., Riley-Gillis, B., Han, L., Jia, Y., Lodi, A., Zhang, H., Ganesan, S., Pan, R., Konoplev, S. N., Sweeney, S. R., Ryan, J. A., Jitkova, Y., Dunner, K., Grosskurth, S. E., Vijay, P., Ghosh, S., Lu, C., Ma, W., Kurtz, S., ... Konopleva, M. (2022). Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3). Signal Transduction and Targeted Therapy, 7(1), Article 110. https://doi.org/10.1038/s41392-022-00958-4

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3). / Zhang, Qi; Riley-Gillis, Bridget; Han, Lina et al.
In: Signal Transduction and Targeted Therapy, Vol. 7, No. 1, 110, 12.2022.

Research output: Contribution to journal › Comment/debate › peer-review

Zhang, Q, Riley-Gillis, B, Han, L, Jia, Y, Lodi, A, Zhang, H, Ganesan, S, Pan, R, Konoplev, SN, Sweeney, SR, Ryan, JA, Jitkova, Y, Dunner, K, Grosskurth, SE, Vijay, P, Ghosh, S, Lu, C, Ma, W, Kurtz, S, Ruvolo, VR, Ma, H, Weng, CC, Ramage, CL, Baran, N, Shi, C, Cai, T, Davis, RE, Battula, VL, Mi, Y, Wang, J, DiNardo, CD, Andreeff, M, Tyner, JW, Schimmer, A, Letai, A, Padua, RA, Bueso-Ramos, CE, Tiziani, S, Leverson, J, Popovic, R & Konopleva, M 2022, 'Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3)', Signal Transduction and Targeted Therapy, vol. 7, no. 1, 110. https://doi.org/10.1038/s41392-022-00958-4

Zhang Q, Riley-Gillis B, Han L, Jia Y, Lodi A, Zhang H et al. Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3). Signal Transduction and Targeted Therapy. 2022 Dec;7(1):110. doi: 10.1038/s41392-022-00958-4

@article{0872b678e58841468a12235ebbfb3e1d,

title = "Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3)",

abstract = "In the original version of this article, given name of 4th author Yannan Jia was incorrectly published as Yanan Jia. The original article has been corrected.",

author = "Qi Zhang and Bridget Riley-Gillis and Lina Han and Yannan Jia and Alessia Lodi and Haijiao Zhang and Saravanan Ganesan and Rongqing Pan and Konoplev, {Sergej N.} and Sweeney, {Shannon R.} and Ryan, {Jeremy A.} and Yulia Jitkova and Kenneth Dunner and Grosskurth, {Shaun E.} and Priyanka Vijay and Sujana Ghosh and Charles Lu and Wencai Ma and Stephen Kurtz and Ruvolo, {Vivian R.} and Helen Ma and Weng, {Connie C.} and Ramage, {Cassandra L.} and Natalia Baran and Ce Shi and Tianyu Cai and Davis, {Richard Eric} and Battula, {Venkata L.} and Yingchang Mi and Jing Wang and DiNardo, {Courtney D.} and Michael Andreeff and Tyner, {Jeffery W.} and Aaron Schimmer and Anthony Letai and Padua, {Rose Ann} and Bueso-Ramos, {Carlos E.} and Stefano Tiziani and Joel Leverson and Relja Popovic and Marina Konopleva",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2022.",

year = "2022",

month = dec,

doi = "10.1038/s41392-022-00958-4",

language = "English (US)",

volume = "7",

journal = "Signal Transduction and Targeted Therapy",

issn = "2095-9907",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Correction

T2 - Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3)

AU - Zhang, Qi

AU - Riley-Gillis, Bridget

AU - Han, Lina

AU - Jia, Yannan

AU - Lodi, Alessia

AU - Zhang, Haijiao

AU - Ganesan, Saravanan

AU - Pan, Rongqing

AU - Konoplev, Sergej N.

AU - Sweeney, Shannon R.

AU - Ryan, Jeremy A.

AU - Jitkova, Yulia

AU - Dunner, Kenneth

AU - Grosskurth, Shaun E.

AU - Vijay, Priyanka

AU - Ghosh, Sujana

AU - Lu, Charles

AU - Ma, Wencai

AU - Kurtz, Stephen

AU - Ruvolo, Vivian R.

AU - Ma, Helen

AU - Weng, Connie C.

AU - Ramage, Cassandra L.

AU - Baran, Natalia

AU - Shi, Ce

AU - Cai, Tianyu

AU - Davis, Richard Eric

AU - Battula, Venkata L.

AU - Mi, Yingchang

AU - Wang, Jing

AU - DiNardo, Courtney D.

AU - Andreeff, Michael

AU - Tyner, Jeffery W.

AU - Schimmer, Aaron

AU - Letai, Anthony

AU - Padua, Rose Ann

AU - Bueso-Ramos, Carlos E.

AU - Tiziani, Stefano

AU - Leverson, Joel

AU - Popovic, Relja

AU - Konopleva, Marina

PY - 2022/12

Y1 - 2022/12

N2 - In the original version of this article, given name of 4th author Yannan Jia was incorrectly published as Yanan Jia. The original article has been corrected.

AB - In the original version of this article, given name of 4th author Yannan Jia was incorrectly published as Yanan Jia. The original article has been corrected.

UR - http://www.scopus.com/inward/record.url?scp=85127391782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127391782&partnerID=8YFLogxK

U2 - 10.1038/s41392-022-00958-4

DO - 10.1038/s41392-022-00958-4

M3 - Comment/debate

C2 - 35365596

AN - SCOPUS:85127391782

SN - 2095-9907

VL - 7

JO - Signal Transduction and Targeted Therapy

JF - Signal Transduction and Targeted Therapy

IS - 1

M1 - 110

ER -

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia (Signal Transduction and Targeted Therapy, (2022), 7, 1, (51), 10.1038/s41392-021-00870-3)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this